Detalhe da pesquisa
1.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet
; 403(10424): 379-390, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109916